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Background/aim: COVID-19 syndrome due to the SARS-CoV-2 virus is a currently challenging situation ongoing worldwide. Since
the current pandemic of the SARS-CoV-2 virus is a great concern for everybody in the World, the frequently asked question is how and
when the COVID-19 process will be concluded. The aim of this paper is to propose hypotheses in order to answer this essential question.
As recently demonstrated, SARS-CoV-2 RNAs can be reverse-transcribed and integrated into the human genome. Our main hypothesis
is that the ultimate aim of the SARS-CoV-2 virus is the incorporation to human genome and being an element of the intestinal virobiota.
Materials and methods: We propose that the SARS-CoV-2 genomic incorporation to be a part of human virobiota is essentially based
on three pathobiological phases which are called as the ‘induction’, ‘consolidation’, and ‘maintenance phases’. The phase of ‘recurrence’
complicates any of these three disease phases based on the viral load, exposure time, and more contagious strains and/or mutants. We
have performed the ‘random walk model’ in order to predict the community transmission kinetics of the virus.
Results: Chimerism-mediated immunotherapy at the individual and community level with the help of vaccination seems to be the
only option for ending the COVID-19 process. After the integration of SARS-CoV-2 virus into the human genome via the induction,
consolidation, and maintenance phases as an element of intestinal virobiota, the chimerism would be concluded. The ‘viral load’, the
‘genomic strain of the SARS-CoV-2’, and ‘host immune reaction against the SARS-CoV-2’ are the hallmarks of this long journey.
Conclusion: Elucidation of the functional viral dynamics will be helpful for disease management at the individual- and communitybased long-term management strategies.
Key words: SARS-CoV-2, COVID-19, virobiota, genomic integration

1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) is a member of coronavirus family which leads to a
respiratory disease like severe acute respiratory syndrome
coronavirus (SARS-CoV). SARS-CoV and SARS-CoV-2
are from the same virus family origin and their features
of structure, genetics, and pathobiology are similar to
each other. Our research group had recently published
that coronaviruses may affect pulmonary tissues and
some critical immune genes play essential roles after their
interaction with renin–angiotensin system (RAS) elements
[1]. Local tissue-based RASs, for instance bone marrow
(BM) RAS [2,3], serve for the dissemination of the SARS-

CoV-2 infection for the genesis of COVID-19 syndrome
associated with macrophage activation [4]. We have
demonstrated that the RAS genes play a significant role
at the initiation of the infections caused by coronaviruses
and may have a strong association with the exchange
of immune genes during the clinical course following
the infection. On the other hand, there are ongoing
discussions regarding the clinical course of COVID-19.
Our team had proposed three critical prominent phases
regarding the clinic-genomic course of the COVID-19
immune syndrome [5]. We have previously disclosed that
the COVID-19 clinical course follows three consequent
periods which are ‘asymptomatic/presymptomatic phase’,
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‘respiratory phase with mild/moderate/severe symptoms’,
and ‘multisystemic clinical syndrome with impaired/
disproportionate and/or defective immunity’. ACE2 and
ANPEP, EGFR and IGF2R, IFN and immune systemrelated critical gene involvements play a role in the first,
second, and third phases, respectively. The separation of
each phase from another with their own different genetic
features enables researchers to focus more appropriately
on the treatment of COVID-19. Comprehensive genomic
profiling with next-generation sequencing may play an
important role in distinguishing between the phases. Our
group had also proposed potential treatment options for
COVID-19. ANPEP gene pathway could be investigated
for the vaccine development. MAS receptor agonists,
TXA127, Angiotensin (1-7) and soluble ACE2 have the
potential to interfere gene expressions thereby altering the
COVID-19 disease course. The genomic editing by future
CRISPR technology has also been discussed as a treatment
option for COVID-19.
Since the current pandemic of SARS-CoV-2 virus is a
great concern for everybody in the world, the frequently
asked question is how and when the COVID-19 process
will be concluded. The aim of this paper is to propose
hypotheses in order to answer this essential question.
Several papers had already pointed out modelling systems
focusing on viral dynamics [6,7]. Zhang et al. recently
demonstrated that SARS-CoV-2 RNAs can be reversetranscribed and integrated into the human genome
[8]. The authors even stressed that the current SARSCoV-2 PCR tests are detecting viral transcripts from
viral sequences stably integrated into the genome rather
than active infectious virus. Thus, routine PCR tests may
neither reflect actual active viral load nor the efficacy of
the treatment to suppress viral replication [8].
2. Materials and methods
Our main hypothesis is that the ultimate aim of the
the SARS-CoV-2 virus is the incorporation to human
genome and being an element of intestinal virobiota.
Prolonged SARS-CoV-2 RNA shedding and recurrence
of PCR-positive tests are evident in asymptomatic healthy
noninfectious individuals because of the viral sequences
stably integrated into the genome [8]. Intestinal SARSCoV-2 colonies are demonstrated during the long-term
course as well [9,10]. We, herein, propose that the SARSCoV-2 genomic incorporation to be a part of human
virobiota is essentially based on three pathobiological
phases which are called the induction, consolidation,
and maintenance phases. This genomic incorporation is
affected by three main factors which are the ‘viral load’,
the ‘genomic strain of the SARS-CoV-2’, and ‘immune
reaction against the SARS-CoV-2’. The immune reaction
against SARS-CoV-2 in the community actually represents
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the third phase of the clinical course of COVID-19 in
human body which is previously described by our group
as ‘multisystemic clinical syndrome with impaired/
disproportionate and/or defective immunity’ [5]. In this
phase, the immune system is impaired which means
that it has lost its balance and malfunctioning so it leads
to the either exaggerated immune response or immune
deficiency. Herein, our group aimed to focus on the concept
of ‘human virobiota’ and ‘genomic incorporation’ of the
SARS-CoV-2 to human virobiota. All countries in the
world are in the different genomic incorporation phases of
the SARS-CoV-2 to human virobiota. The stage of genomic
incorporation phase in the community is directly related
with the mortality of the COVID-19 in each population.
Integration of the viral genome into the host cell genome
is a very complicated process [11]. Chimerism-mediated
immunotolerance between the virus and human seems to
be the only solution for this ongoing pandemic. Cellular
immunity, particularly the T cells, could have the most
significant impact on the generation of immune tolerance
and host-virus chimerism [12–15]. The importance of
protective mucosal T-cells against SARS-CoV-2 could take
place within the chimerism-mediated immunity including
the intestinal system [16].
The induction phase of genomic incorporation
exerts all three phases of the COVID-19 syndrome in
human body which are ‘asymptomatic/pre-symptomatic
phase’, ‘respiratory phase with mild/moderate/severe
symptoms’ and ‘multisystemic clinical syndrome with
impaired/disproportionate and/or defective immunity’.
One exception of this is the COVID-19 syndrome in
pediatric age. In children, COVID-19 generally presents
with ‘asymptomatic/pre-symptomatic phase’, ‘respiratory
phase with mild/moderate/severe symptoms’, and do not
reach the last phase of the disease. The potential reason of
this finding could be the unique gene expressions in each
phase and the difference between the gene expressions of
adult and child COVID-19 patients. The assumption is that
the majority of the countries in the world will complete
the induction genomic incorporation phase in summer
2020 and proceed to the consolidation phase of genomic
incorporation of the SARS-CoV-2 to human virobiota.
The consolidation phase of genomic incorporation
exerts generally the first two phases of the COVID-19
syndrome in human body, which are ‘asymptomatic/
presymptomatic phase’, ‘respiratory phase with mild/
moderate/severe symptoms’. The phase of ‘recurrence’
complicates any of these three disease phases based
on the viral load, exposure time, and more contagious
strains and/or mutants. We assume that we are currently
in the recurrence phase with the disease spreading in our
community. We assume that the majority of the countries
in the world will complete the consolidation genomic
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incorporation phase in middle or late 2021, unless a phase
of ‘recurrence’ does not complicate any given community
because of the high viral load within a relatively short
exposure time with more contagious SARS-CoV-2 strains
and/or mutants [17].
We assume that the maintenance phase of genomic
incorporation will exert generally only the first phase
of the COVID-19 syndrome in human body which is
‘asymptomatic/presymptomatic phase’. We have performed
the ‘random walk model’ in order to predict the course
of genomic incorporation stages of the SARS-CoV-2 to
human virobiota.
COVID-19 death rate data is hard to forecast. We
believe that these rates move like random walk. After
taking first differences of the data, our data behaves
like noise. Random walk model solves the uncertainty
problem for more than 1 period. Our model also makes a
benchmarking for the death rates. Random walk model is
common in forecasting irregular time series data. Model
forecasts the change between two periods. Therefore, the
first difference of the series is a predictable pattern. Error
terms must be independent and identically distributed
(iid) in random walk model. The forecasted sample is
independent from historical data. These models are
denoted as below. Yt is the value of forecasted data in time
t, Yt-1 is the value that is one period before and error term is
iid. is the autocorrelation coefficient that satisfies | ρ | < 1.
Yt=ρ×Yt-1+εt
If we divide Yt-1 from both sides, then we have
error term as the change between two periods which is

independent from past movements (). Error term depends
only on period t and t-1 values of Y. Then we have Yt as
denoted from Y0. Here we do not have drift component.
εt=Yt-Yt-1
t-1
Yt=Y0+∑ i=0
εt-i
Our group estimates that after the middle of 2021,
the pandemic will reach its last phase with an extensive
spread throughout the world but a very low mortality rate
compared to the first and second phases. In this last phase,
SARS-CoV-2 will become a part of human virobiota and
the human immune system will accept the presence of the
SARS-CoV-2. Therefore, human immune system will not
be reactive against SARS-CoV-2 that enables patients to
have a much more improved clinical course. The patients
will probably have a mild clinical course as the clinical
course of an influenza virus (Figure 1).
During our analysis of the COVID-19 cases in large
communities, we have found that besides the proposed
three phases, there is another phase of ‘recurrence’ that
emerged because of high viral load within a very short
time period and/or different viral strains or mutants [18].
However, we suggest that this phase is temporary and
communities will eventually return to the consolidation
or maintenance phases (Figures 1–3). We also predict that
maintenance phase of genomic incorporation to human
virobiota will last around 5 years (Figure 3).
To show the alterations in IFN genes, GSE17400 data
was normalized using the RMA method [1]. When the
expression of genes belonging to cells infected with SARSCoV for 12 h was compared with the group infected for

Figure 1. The proposed SARS-CoV-2 phases of genomic incorporation to human genome as a part of intestinal virobiota in large
communities.
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Figure 2. COVID-19 death rates in Turkey from beginning of the COVID-19 pandemic in Turkey. Induction phase of the COVID-19
has ended on 10th June 2020, and between 11th June and 26th August 2020 Turkey has experienced the consolidation phase of the
COVID-19 pandemic. From 27th August, the recurrence phase of the COVID-19 has started in Turkish community.

Figure 3. The prediction of the COVID-19 death rates in the Turkish community. We have applied the ‘random walk model’ in order to
predict the course of genomic incorporation stages of SARS-CoV-2 in the Turkish community virobiota. We assume that the Recurrence
phase ended in the middle of October 2020 and eventually Turkish community will return to the Consolidation phase. We have predicted
that Turkish community would enter the maintenance phase in mid-2021.
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48 h; it was determined that 34 probe sets belonging to
23 genes that were expressed statistically significantly and
differently. Among these genes, a total of 17 genes were
found to increase in expression as the virus treatment
process progressed, while a decrease in the expression of
other genes was observed (Figure 4).

3. Results
3.1. Evaluation of the ‘three-phase’ hypothesis
3.1.1. Initial phase of COVID-19
In this phase, the COVID-19 patients are either
asymptomatic or presymptomatic. If patients are
asymptomatic, they have no signs or symptoms and they

Figure 4. The expression of genes belonging to cells infected with SARS-CoV for 12 h was compared with the group infected for 48 h. It
was found that 34 probe sets belonging to 23 genes were expressed statistically significantly and differently. Among these genes, a total
of 17 genes were found to increase in expression as the virus treatment process progressed, while a decrease in the expression of other
genes was observed.
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complete the clinical course without any complication. If
patients are presymptomatic, then they have either present
with respiratory form or intestinal form. In the respiratory
form of initial phase of the COVID-19, patients may have
sore throat, mild fever, dry cough, and nasal congestion.
In the intestinal form of initial phase of the COVID-19,
patients may have ageusia, anosmia, and diarrhea. Our
group previously published that ACE2 and ANPEP genes
play major roles in the initial phase of the COVID-19 [5].
3.1.2. Propagating phase of COVID-19
In the propagating phase of the COVID-19, patients’
symptoms start to worsen. They may have mild to
moderate or severe symptoms. Many organ systems may
be involved in this phase. Patients may have respiratory,
cardiovascular, hematopoietic, renal and other organ
system involvements. In the respiratory system, patients
may have pneumonia and the involvement of lung tissue
which can be confirmed by imaging techniques. In the
cardiovascular system, patients may have arrhythmias,
acute cardiac injury, and myocarditis [19]. In the
hematopoietic system, patients may have lymphopenia and
thromboembolic complications [20]. In the renal system,
patients may have acute renal injury [21]. Moreover, in
this phase, conjunctivitis, dactilitis, hepatitis, cutaneous
involvements like maculopapular, urticarial, and vesicular
eruptions, and transient livedo reticularis may be seen in
the COVID-19 patients [22–24]. Our group previously
published that EGFR and IGF2R genes play major roles in
the propagating phase of COVID-19 [5].
3.1.3. Complicating phase of COVID-19
The complicating phase of the SARS-CoV-2 is the phase
where the disease mostly ends up with mortality. In this
phase, SARS-CoV-2 is already spread all over the body.
Autopsy studies have noted detectable SARS-CoV-2 RNA
(and, in some cases, antigen) in the kidneys, liver, heart,
brain, and blood in addition to respiratory tract specimens,
suggesting that the virus disseminates systemically [25].
In the complicating phase of SARS-CoV-2, patients are
in severe and critical clinical condition. In this phase, the
immune system is impaired, which means that it has lost
its balance and is malfunctioning so it leads to the either
exaggerated immune response or immune deficiency.
Acute respiratory distress syndrome (ARDS) and
multiorgan failure (MOF) are seen in most of the patients
in this phase [19]. Patients are followed in the intensive
care units and generally with mechanical ventilation
support. Secondary infections are frequently seen in this
phase which eventually leads to sepsis and septic shock
[26]. Our group previously published that IFN and other
immune genes play major roles in the complicating phase
of the COVID-19 [5].
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3.2. Empirical data
3.2.1. Human genomic incorporation of SARS-COV-2, a
journey to the intestinal virobiota
In recent years, so as to comprehend the relationship
between humans and viruses in more detail, the concept
of virobiota become more popular. Virobiota generally
implies a community of viruses. The physiological roles
of virus population presences in the host are not fully
known, while it is predicted that they attempt to survive
in host cells. Some studies illuminate that human virobiota
typically consists of some bacteriophages and mostly
viruses. In addition to these, the mentioned partnership
may have the potential to benefit the host depending on
the functions of the viruses. On the other hand, it could
also cause serious damage to the cells of the host [27–29].
One of the most significant biological steps affecting the
host’s virobiota is the incorporation of a virus’s genome into
the host. Proper understanding of the concept of genomic
incorporation plays a crucial role in the development
of this effect. This idea implies the transfer of the virus’s
genetic material to the target host; it also implies that this
incorporation is critical for the survival of the virus’s own
functionality. For instance, once the virus transfers its
genetic information to the host cell, it can propagate its
numbers, which creates the possibility to replicate itself. In
the genomic incorporation process, there are vital factors
needing attention. Viral load, genomic strain, and immune
reaction against the virus are three highly core factors
[11,30].
Studies have shown that viral load has importance in
the process of incorporating the genetic material of the
virus to its target host. The data recorded in 2016 predicted
that the viral load, which is not emphasized and cannot
be determined in detail, may adversely affect the progress
of the disease triggered by the virus. In another similar
study, it was observed that high viral load in genomic
incorporation increased the rate of disease development.
This increased speed may cause the resistance of the cells
to decrease and delay the immune response by putting
pressure on the host cells. If infected individuals can
alleviate the viral load triggered by the virus, they can
also slow the progression of the disease. In that part,
the immune reaction created against the virus infection
could take place. These reactions can happen in two
ways: immune depression and hyperinflammation due
to overreaction between host and virus. These reactions
have ability to lead to the serious process of genomic
incorporation of virus [30,31].
In addition to the viral load and immune reactions,
genomic strain of virus is another determinative factor
for genomic incorporation of the virus, specifically SARSCoV-2. According to a research, the strains of the SARSCoV-2 virus are determined as an outcome of mutation.
This will help to change the severity of the COVID-19
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disease. The strains should be comprehended regarding
the functionality of the genomic strains because this
could change the entering criteria as well as genomic
incorporation of the SARS-CoV-2 virus into host’s cells.
One mutation could make the SARS-CoV-2 virus more
aggressive and then, some property of virus can alter
regarding the transmissibility and severity [32].
A recent study depicted SARS-CoV-2 fecal viral
activity in association with gut microbiota composition
in patients with COVID-19 [16]. The result of this study
favors that the middle- or long-term target of SARS-CoV-2
is to incorporate into the intestinal virobiota of the human
body [16]. It is probable that intestinal local RAS system
may play an important role in the genomic incorporation
of SARS-CoV-2 to the human intestinal virobiata. In this
study, we have applied the ‘random walk model’ in order to
predict the course of genomic incorporation stages of the
SARS-CoV-2 in the human virobiota (Figure 3). Intestinal
SARS-CoV-2 colonization had recently been documented
supporting our view of virobiota [9,10].
4. Discussion
4.1. Induction phase of the SARS-COV-2 genomic
incorporation
As considering the stated information, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2)
incorporates its own genome to the human genome. This
genomic incorporation performed by SARS-CoV-2 is
predicted within the scope of this study that the induction
phase plays a role in the part of genomic incorporation.
The induction phase could be regarded as the first attack
of the SARS-CoV-2 virus. The study conducted by Malkan
et al. illuminated that SARS-CoV-2 acts in initiating,
propagating, and complicating phases [5]. This virus
was able to take place in initiating, propagating, and
complicating phases during the time period of induction
phase. The SARS-CoV-2 coronavirus primarily targets
the ACE2 receptor. The reason behind this targeting is
entering into cells as a result of causing alteration to the
normal functions of ACE2. The ACE2 receptor enables
S proteins to be activated and the stimulated S proteins
support the SARS-CoV-2 virus to enter the host cells.
With this entering, the virus could incorporate its genetic
material into cells. Furthermore, during the entry time
interval, the virus gains time for its replication. This
incorporation can even be expressed as the initiating
phase. Significantly, the change in expression is primarily
observed in the lungs at the ACE2 protein level during
this phase, which should be taken into account. Following
the initiating phase, it is supposed that SARS-CoV-2
enters the propagating phase. This change also suggests
progression to the lower respiratory tract. Additionally,
the development could refer to changes in the expression
levels of related different genes. In the same study, EGFR

and IGF2R genes demonstrate the difference expression.
The difference in the expression levels in both genes leads
to the weakening of the activation in the innate immune
system. The SARS-CoV-2 virus turns this weakening in
its favor and accelerates the increase in numbers causing
the severe damage to the host such as multiorgan failure.
Alteration in gene expression levels that develop in the
induction phase facilitates the entry of the SARS-CoV-2
virus into the host cell, leading to a weakening of the
immune response that may occur early. Finally, it is known
that there is a possibility that the SARS-CoV-2 virus may
switch to the complicating phase during the induction
phase. In this phase, the production of interferon as well
as cytokine, which have a critical part in the development
of immune response, changes cytokine production.
Genes associated with immunity play an active role in the
complicating phase, which can be regarded as the last stage
of the induction phase. Differences in the expression levels
of these genes can express the damage that the virus may
cause. The cytokine and interferon produced constitute
the first line of host defense despite the SARS-CoV-2 virus
entering the cell [5,33].
In this induction phase, the lung is the main target for
the SARS-CoV-2 virus. Generally, it causes pneumonia in
this area. Pneumonia indicates specific inflammation that
happens in the lungs. During this first attack, the human
immune system dynamically works and the normal
working function of T cell misleads take place in 3 phases
[5]. The management of the induction phase of SARSCoV-2 genomic incorporation could be achieved by test,
trace, and isolate method. The suspected COVID-19 cases
should be tested using appropriate methods and then the
possible contacted cases should be traced, and finally the
diagnosed cases should be isolated. This management
strategy could be successful with the help of using masks,
social distancing, and abiding by hygiene principles [34].
If needed, lockdown of the community may be used to
control the disease in this phase of SARS-CoV-2 genomic
incorporation.
The COVID-19 pandemic has been the subject of
many scientific studies worldwide and in Turkey [35]. In
the viral infection process, IFNs have important direct
or indirect roles in the entry of the infectious agent into
the host cell and its replication within the cell, and in
the immune response that the host generates. In parallel
with the results of studies conducted by other researchers,
in our results, the symptoms and severity of the clinical
picture in COVID-19 are directly related to the host’s IFN
response [5,36]. In the literature, it was proposed that early
induction of IFN-γ-secreting SARS-CoV-2-specific T cells
occurs in the COVID-19 cases with mild to moderate
disease and accelerated viral clearance [37]. Intestinal
SARS-CoV-2 colonization associated with IFN response
as the critical step of the inclusion into the virobiota
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usually follows the resolution of the clinical symptomatic
viral infection.
In our results, while the expression of the 17 IFN genes
is low at the beginning of the infection with SARS-CoV, as
the time of treatment with the virus progresses, an increase
in the expression of these genes is observed in lung
epithelial cells. IFNAR2 from the type I interferon family
and IFNLR1, a type III interferon, are two interferons that
are effective in the viral replication process [36,38–41].
Two other important genes whose expression is increased
as the exposure time to the infectious agent increases are
IFNL1 and IFNL2 genes. High expression of these genes
leads to an increase in the tumor necrosis factor [42,43].
Our results show that the expression of some genes
in the interferon family is reduced as a result of infection
progression. There may be different reasons for this. The
generation of a measured IFN response can protect the host
from the destruction of the proinflammatory response due
to IFNs [44]. On the other hand, it has been shown that in
some viral infections, the virus can inhibit the interferon
release of the host [45].
4.2. Consolidation phase of the SARS-COV-2 genomic
incorporation
Another genomic incorporation phase of the SARSCoV-2 virus after the induction phase is the consolidation
phase. The consolidation phase is assumed to occur in
the upper respiratory tract, unlike the induction phase.
The fact that the SARS-CoV-2 virus can pass to initiating
and propagating phases constructs the basis of the
consolidation phase. As stated in the induction phase, in
the initiating phase, the SARS-CoV-2 virus tries to enter
the host cells. The entering mechanism utilized by the
SARS-CoV-2 virus is similar to the mechanism used by the
SARS-CoV virus. The most significant of this similarity is
the change in the expression level of the ACE2 receptor.
Organs that increase ACE2 expression, such as the lung,
are among the fundamental targets of the SARS-CoV-2
virus. The protein called spike or S glycoprotein associated
with this receptor facilitates the virus to be incorporated.
With the entry of the virus into the host cell, its genetic
material is specifically transferred to the cytoplasm of the
cell, and this transfer leads to an elevation in the number
of replications of the virus. This rise in number aids to
stimulate the immune response of the host cell [5,46].
When the virus progresses from the initiating phase,
the functionality of the propagating phase emerges. This
phase is perceived as the phase in which the damage
produced by the virus is largely determined. During the
propagating phase, a reduction in the expression levels
of some immune-associated genes would be observed,
as stated in the induction phase, and this decline
correspondingly causes the immune response to be
developed in the early phase. In the induction phase, the
propagating phase was followed by the complicating phase

1008

due to severe damages that occurred at this stage. However,
it is predicted that the complicating phase is not seen in
the consolidation phase. In this case, changes occurring
in the immune system at the molecular level take place as
the main factor. With the activation of the S protein in the
initiating phase, the mechanism of action of the Toll-like
receptor 7 (TLR-7) located in the endosome during the
genomic incorporation phase of the SARS-CoV-2 virus,
becomes functional. Thanks to the active status of TLR-7,
it supports the production of cytokines that is so crucial
in the attack against the virus. In addition, with the aid
of the activity of TLR-7, some signal pathways such as
nuclear factor κB (NF-κB) and Janus kinase transducers
(JAK / STAT) and transcription factors such as interferon
response factor (IRF3), which are important under the
influence of the virus, could be triggered. As considering
these important pathways expressed as an example, the
transition to the complicating phase can be prevented by
presenting a noteworthy immune response due to the fact
that the production of interferon and cytokine against the
virus is strengthened at a certain rate. In fact, the decrease
in mortality when examined from the first encounter time
with the virus to the current period supports this situation
[46].
The management of the consolidation phase of SARSCoV-2 genomic incorporation could be achieved by test,
trace, and isolate method. The suspected COVID-19 cases
should be tested using appropriate methods and then the
possible contacted cases should be traced and finally the
diagnosed cases should be isolated. This management
strategy could be successful with the help of using masks,
social distancing, and abiding by hygiene principles.
Lockdown of the community should not be used to
control the disease in this phase of SARS-CoV-2 genomic
incorporation.
4.3. Recurrence phase of the SARS-COV-2 genomic
incorporation
In this temporary genomic incorporation phase of
recurrence, communities exposed to high viral load
within a very short time period and/or different viral
strains. Appropriate management of communities will
eventually lead to transforming the recurrence phase to the
maintenance or consolidation phases. The management
of the recurrence phase of SARS-CoV-2 genomic
incorporation could be achieved using test, trace, and
isolate method. The suspected COVID-19 patients should
be tested using appropriate methods and then the possible
contacted cases should be traced and finally the diagnosed
cases should be isolated. This management strategy
could be successful with the help of using masks, social
distancing, and abiding by hygiene principles. Lockdown
of the community should not be used to control the disease
in this phase of SARS-CoV-2 genomic incorporation. Our
country, Turkey, had been hit by that ‘recurrence’ phase
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following the reopening of the community crowds, which
was controlled via further restrictions and reinstitution of
the wide test–trace–isolate strategy.
4.4. Maintenance phase of the SARS-COV-2 genomic
incorporation
In addition to the induction and consolidation phases,
maintenance phase could take place in the future period of
SARS-CoV-2 infection. The clinical course of maintenance
genomic incorporation phase in adult patients will be like
the present COVID-19 clinical course in the children. In a
recent study, it was reported that the SARS-CoV-2-specific
IgA and limited inflammatory cytokines are present in the
stool of selected patients with acute COVID-19 [47]. This
study favors that the SARS-CoV-2 tends to incorporate
into the intestinal virobiota. From our point of view,
the maintenance period will probably start (probably in
the spring of 2021) when the SARS-CoV-2 achieves the
genomic incorporation into the homo sapiens’ intestinal
virobiota. In the literature, it was stated that 20% infected
population is enough for achieving herd immunity [48].
Therefore, %20 SARS-CoV-2 infected population is
necessary for community to achieve the maintenance
phase of SARS-CoV-2 genomic incorporation. On the
other hand, SARS-CoV-2 can have mutations which may
facilitate the genomic incorporation of SARS-CoV-2 into
human virobiota. In a recent study, it was found that
a major deletion in the SARS-CoV-2 genome leads to a
decrease in the severity of infection and the inflammatory
response [49]. Another recent study also reports the
evidence of mutations of SARS-CoV-2 [50]. These
mutations may lead to acceleration in the transformation
of communities into the maintenance phase of SARSCoV-2 genomic incorporation. The maintenance phase of
genomic incorporation could mimic the current pediatric
SARS-CoV-2 clinicopathological course in adults with
rare progression of the COVID-19 syndrome to terminal
complication phase (Figure 1).
The most significant aspect of this phase is that the
SARS-CoV-2 virus could display only the initiating phase,
which was described in detail in the study of Malkan et al.
[5]. Maintenance phase represents the entry of the SARSCoV-2 virus into the host cell as well as the incorporation
of its genetic material. After the genomic incorporation
progression, it is predicted that the immune response
described in the consolidation phase shows a significant
increase in the functions of mechanisms with important
functions such as TLR-7 and IFN3 at the molecular
level. Moreover, it is believed that the damage caused
by the virus in the host will be weakened thanks to this
activation, and thus blocking the transition to severe
phases such as propagating and complicating. In other
words, this situation could allow the disease to be overcome
presymptomatically. Besides, it is foreseen within the scope
of this study that the SARS-CoV-2 virus can survive in

the intestine, nervous system, and endothelial cells in the
maintenance phase. According to some specific studies,
the SARS-CoV-2 entering responsible receptor, ACE2
expressed in many different critical organs such as lung,
intestine, heart as well as in endothelial cells. Furthermore,
those studies and analyses underline the possible outcomes
that the SARS-CoV-2 virus would be included under the
human intestinal virobiota [47,51].
The management of the maintenance phase of SARSCoV-2 genomic incorporation could be achieved by abiding
by hygiene principles. Testing and tracing of suspected
cases and isolation methods are not needed in this phase.
Using masks and social distancing will not be necessary
in this last phase of the disease genomic incorporation. If
anytime an effective vaccine can be found for SARS-CoV-2,
then the maintenance phase can begin earlier than mid2021 or the reoccurrence phase can be prevented [52,53].
Maintenance phase could last 2 to 5 years based on the
level of passive, active, natural community immunity. It is
hoped that widespread vaccination against SARS-CoV-2
could be helpful for the shortening in the duration of the
COVID-19 transmission phases.
5. Conclusion
COVID-19 syndrome due to SARS-CoV-2 virus is
currently a challenging situation ongoing worldwide.
Newly emerging mutant viruses such as United Kingdom
variant B.1.1.7, South African variant B1351, and
B.1.1.7+E484K mutant combination could produce their
own induction–consolidation–maintenance–recurrence
community phases with distinct virulence/mortality
profiles. Overall infectious pattern and the resulting
disease aggressiveness of the wild and mutant SARSCoV-2 colonies will determine the global course of the
pandemic within years.
Chimerism-mediated immunotherapy seems to be the
only option for ending the COVID-19 process. After the
SARS-CoV-2 virus is incorporated to the human genome
via the induction, consolidation and maintenance phases
as an element of intestinal virobiota, the chimerism will be
concluded. The ‘viral load’, the ‘genomic strain of SARSCoV-2’, and ‘immune reaction against SARS-CoV-2’
are the hallmarks of this long journey. Elucidation of
the functional viral dynamics will be helpful for disease
management at the individual- and community-based
long-term strategies.
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